COMMUNIQUÉS West-GlobeNewswire

Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评
21/04/2026
FDA 授予 Daretabart (hu1418K322A) 快速通道认定资格，以解决高危神经母细胞瘤领域存在的重大未满足医疗需求，允许该药物进入加速评审和滚动审评流程 FDA 通过新药临床研究 (IND) 申请后，即可在高危神经母细胞瘤复发及难治性患者中启动 SHINE II/III 期临床试验 Daretabart (hu1418K322A) 第一个商业化规模 GMP 生产批次已顺利完成项目基于 II 期的积极数据， [...]
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
20/04/2026
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half [...]
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
20/04/2026
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Amwell® to report first quarter 2026 operating results
20/04/2026
BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report first quarter 2026 operating results [...]
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
20/04/2026
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that [...]
Spectral AI Announces Annual Meeting of Stockholders
20/04/2026
DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
FibroBiologics Compliant with All Nasdaq Listing Requirements
20/04/2026
HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/04/2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced [...]
Moonbird Claims Evaluated: Guided Breathing Therapy Device for Meditation-Like Calming Benefits for Relaxation & Sleep Support
21/04/2026
A 2026 informational overview of Moonbird's tactile breathing coach technology, EEG brain scan research references, real-time HRV biofeedback, pricing structure, and what prospective buyers should know before ordering [...]
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
20/04/2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
20/04/2026
First‑in‑class DARKFOX‑targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX‑A3 peptide presented by HLA‑A*03:01, a highly prevalent HLA allele, enabling precise redirection of T [...]
FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
20/04/2026
Major Carriers Accelerate Route Cuts as Economics Break Down, Creating Multi-Billion-Dollar Opportunity in Regional Air Mobility Flyte Expands Focus on High-Frequency Short-Haul Routes to Capture Surging Demand as [...]
IBA – ACQUISITION OF OWN SHARES
20/04/2026
Louvain-la-Neuve, Belgium, April 20 th , 2026 – 9 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
IBA – ACQUISITION D’ACTIONS PROPRES
20/04/2026
Louvain-la-Neuve, Belgique, 20 avril 2026 – 21h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Herz P1 Smart BPM Under Investigation: Clinical-Grade Blood Pressure Monitoring for Valuable At-Home Health Tracking Support
20/04/2026
A 2026 informational overview of Herz P1 Smart BPM FDA 510K clearance, wrist blood pressure monitor accuracy considerations, irregular heartbeat detection features, at-home cardiovascular tracking awareness, and key [...]
AB Science : Nouvelle publication sur medrxiv démontrant des bénéfices substantiels en termes de survie et de qualité de vie préservée avec le masitinib chez les patients atteints de SLA
20/04/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR MEDRXIV DÉMONTRANT DES BÉNÉFICES SUBSTANTIELS EN TERMES DE SURVIE ET DE QUALITÉ DE VIE PRÉSERVÉE AVEC LE MASITINIB CHEZ LES PATIENTS ATTEINTS DE [...]
ViriFlow Claims Evaluated: The Prostate-Supporting Formula for Men That Actually Works in Viri Flow Drops Reviewed
20/04/2026
A 2026 informational overview of ViriFlow's hard water mineral theory, saw palmetto and iodine-rich seaweed blend research, proprietary blend dosing transparency, liquid dropper format considerations, prostate [...]
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
20/04/2026
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS Masitinib treatment [...]

Pages